1 The abbreviations used are: ACE, angiotensin-converting enzyme; gACE, testicular or germinal ACE; sACE, pulmonary or somatic ACE; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PMA, phorbol 12-myristate 13-acetate; PKC, protein kinase C; RTE cells, renal proximal tubule epithelial cells; PAO, phenylarsine oxide; ER, endoplasmic reticulum; MAPK, mitogen-activated protein kinase; MDC9, metalloproteinase/disintegrin/cysteine-rich protein 9; β-APP, β-amyloid precursor protein; TNF-α, tumor necrosis factor-α; TACE, tumor necrosis factor-α-converting enzyme; BiP, immunoglobulin heavy chain binding protein; FACS, fluorescence activated cell sorter. including a specific inhibitor of protein kinase C that, however, could block the enhancement of cleavage-secretion elicited by phorbol ester. These results indicate that ACE tyr-phosphorylation, probably in the endoplasmic reticulum, enhances the rate of its cleavage-secretion at the plasma membrane using a regulatory pathway that may involve p38 MAP kinase.
INTRODUCTION
Renin-angiotensin system is considered a major regulator of fluid homeostasis, electrolyte balance and blood pressure. Angiotensin converting enzyme (ACE), a key component of this system, converts the inactive precursor angiotensin I to the active pressor hormone angiotensin II (1) . It also inactivates bradykinin, a vasodilator. The role of ACE within the reninangiotensin system is well established and inhibition of this enzyme is routinely used for therapeutic management of hypertension. ACE-like proteins have been identified in lower organisms, such as Drosophila (2, 3) , indicating it is an evolutionary conserved protein which also shows an overall sequence homology of 80-90% across mammalian species. This evolutionary importance of ACE coupled with its widespread distribution in many organs within a species, suggest, that over and above its role in the renin-angiotensin system, ACE probably plays a much broader role in general physiology. This notion is supported by the severely abnormal phenotype of ACE knockout mouse (4-6).
There are two different isozymic forms of ACE. These are derived from the same gene by tissue specific choice of alternative transcription initiation sites. The larger somatic ACE (sACE), a component of the renin-angiotensin system, is expressed in vascular endothelial cells, renal proximal tubule epithelial (RTE) cells, intestinal brush border cells, macrophages, and monocytes. The smaller germinal ACE (gACE) is expressed exclusively in the maturing sperm and is involved in male reproduction (7) . Each isozyme contains unique N-terminal domain, but share identical C-terminal domain, including their common zinc-binding active site motif, the hydrophobic membrane anchor and the short cytoplasmic tail (8) (9) (10) (11) . There is a 67% identity between the N-and the C-domains of sACE. Because of the large degree of common C-domain structure including the catalytic active site (His-Glu-X-X-His) in the middle, both C-and Ndomain of sACE, and gACE cleave angiotensin I to generate angiotensin II in vitro (12, 13) . In addition to the membrane-associated form, ACE also exists as a soluble protein. We have shown before that a membrane associated protease, the ACE-secretase, acts on both ACE isozymes to 
Cleavage secretion of biotinylated cell-surface ACE
ACE 89 cells were grown in 100 mm-dishes, washed three times with ice-cold PBS (pH 8) and biotinylated with 0.5 mg/ml of sulfo-NHS-LC-biotin (Pierce) in PBS for 45 min at 4ºC.
Unreacted biotin was quenched and removed by three washes with ice-cold 0.05M Tris-HCl, pH 8.0 at 4ºC. Biotinylated cells were then transferred to serum-free culture media pre-warmed to 16ºC, with or without 100µM pervanadate for desired time. After the incubation, cells were immediately chilled on ice, the culture media clarified by centrifugation and the cell extract prepared as mentioned earlier. ACE was immunoprecipitated from aliquots of cell extract and culture media by polyclonal ACE antiserum, analyzed by SDS-PAGE and transferred to nitrocellulose membranes. After blocking the membranes with bovine serum albumin (3%) in 20 mM Tris-HCl, pH 8.0 containing 0.05% Tween, the biotin labeled ACE was quantitated by Western blotting with streptavidin-horseradish peroxidase (Pierce) diluted 1:500,000 with the blocking buffer; signals were detected by an enhanced chemiluminescence detection system and quantitated by Scion Image beta 4.0.2. In a complementary assay biotinylated ACE from similar aliquots of cell extract and culture media were precipitated by immobilized streptavidin gel (Pierce), analyzed by SDS-PAGE, Western blotted with anti ACE antibody and quantified as mentioned above. In the experiments where effect of monensin on cleavage-secretion was monitored, the cells were first preincubated with 10µM monensin for 1 hour at 37ºC, chilled on ice before cell-surface proteins were biotinylated. Monensin was present throughout the experiment.
Immunoprecipitation and Immunoblottings with Tyrosine phosphate Antibody
ACE89 cells were labeled and incubated with various agents, as described above. At the end of the incubation, the culture media were discarded and cell lysates were prepared in RIPA buffer (1% Triton X-100 in 50 mM Tris-HCl buffer, pH 7.4, 0.15 M NaCl, 1 mM EDTA and 0.1% SDS (8)), containing 1 mM Na 3 VO 4, 1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail. Immunoprecipitation with anti-tyrosine phosphate antibody (5 µl) and SDS-PAGE analysis were conducted, as mentioned above, except that RIPA buffer described above was used for immunoprecipitation. The electrophoretically separated samples were transferred to Problot membranes (Applied Biosystems, Foster City, CA) for Western blotting. Membranes were blocked with 5% milk in phosphate buffered saline containing 0.05% Tween for 1 h prior to incubation with tyrosine phosphate antibody (1:1000) in the same buffer for 1 h at room temperature. The membranes were washed with phosphate buffered saline containing 0.05% Tween, then treated with horseradish peroxidase-conjugated anti-mouse antibody; signals were detected by an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, NJ). For MS analysis described in Fig 3, 16 cm gels and corresponding trans-blot-cells (BioRad) were used instead of minigel.
Enzyme Activity Measurement
ACE activity was assayed by using hippuryl-L-histidyl-L-leucine (Hip-His-Leu) as the substrate and measuring fluorometrically the His-Leu liberated at 5 mM Hip-His-Leu (20) . To measure ACE activity in RTE cells isolated as described earlier (15) , the cell pellets were extracted with 50 mM Tris-HCl, pH 8, containing 0.1% Triton X-100 and 300 mM NaCl for 1 h. After centrifugation at 50,000 g for 20 min, the supernatant containing solubilized sACE was appropriately diluted and assayed as described above (15) .
Sequencing and identification of Phosphotyrosine containing Proteins
The proteins were identified by sequencing the peptides formed by an in-gel tryptic digestion using LC-tandem mass spectrometry (MS) (21) . Briefly, each band is cut from the gel, reduced, and alkylated prior to treatment with trypsin. The peptides that formed by the digestion are extracted from the polyacrylamide and the digest concentrated by evaporation to approximately 25 µL. The LC-tandem MS system is a Finnigan LCQ-Deca ion trap mass spectrometer system with a Protana microelectrospray ion source interfaced to a 10 cm x 50 µm id C18 reversed-phase capillary chromatography column. Two µL volumes of the digest are injected and the peptides are eluted from the column by an acetonitrile gradient at a flow rate of 0.2 µL/min. The mass spectrometry data are recorded using the data dependent capability of the instrument to acquire full scan mass spectra (to determine peptide molecular weights) and collisionally induced dissociation (CID) spectra (to determine amino acid sequence) in successive instrument scans. This mode of analysis produces approximately 1500 CID spectra, although not all spectra are derived from peptides. The data are analyzed by using all CID spectra collected to search the NCBI non-redundant database with the search program TurboSequest. All matching spectra are verified by manual interpretation. 
RESULTS

Cleavage-secretion of ACE is stimulated by pervanadate
ACE is cleaved and secreted into the culture media from various transfected cell lines and primary cultures. ACE89 cells, a mouse mammary epithelial cell line transfected with rabbit gACE, synthesize large quantities of gACE that are transported to the plasma membrane, where gACE is proteolytically cleaved and the entire ectodomain is secreted into the culture media. To determine the effect of pervanadate on cleavage-secretion of gACE, pervanadate was added to the culture media of ACE89 cells and the enzyme activity of cleaved gACE in the culture media was measured to quantitate secretion. As shown in Fig 1A, ACE activity in the culture media of pervanadate treated cells increased more rapidly than that of the untreated cells. For example, after 30 min, ACE activity present in the culture media of pervanadate treated cells was threefold higher than that present in the media of untreated cells (600 vs 200 units respectively). The increased rate of secretion was detected as early as five minutes after the addition of pervanadate.
To confirm this observation, biosynthesis and cleavage-secretion of gACE was monitored by pulse chasing of newly synthesized gACE followed by immunoprecipitation of gACE from the cell extract and the culture media. The effect of pervanadate on the cleavage-secretion process was examined by its inclusion in the culture media as described above. As expected, the 116 kDa mature gACE, and its 95 kDa underglycosylated precursor, were immunoprecipitated from the cell extract (Fig 1B) . The culture media showed the presence of the 108 kDa mature cleaved gACE, indicating that gACE is secreted out at a low rate in unstimulated cells (8, 17) . In pulse-chase experiments, cleavage-secretion is expressed as the amount of secreted ACE in the media as a percentage of total mature ACE in the cell extract and media combined. Presence of pervanadate increased the rate of cleavage-secretion from 13 ± 2% in unstimulated cells to 58 ± 5% in pervanadate stimulated cells (Fig 1B and C) . Taken together, these experiments confirmed that pervanadate significantly enhanced the cleavage-secretion of gACE in a time and concentration dependent manner. Similar, but less pronounced effect was observed when orthovanadate, a less potent inhibitor of tyrosine phosphatases, was used (data not shown).
Phenylarsine oxide, a different tyrosine phosphatase inhibitor, also increased cleavage-secretion ( Fig 1D) in a similar fashion.
We have shown previously, that cleavage-secretion of ACE is insensitive to large number of inhibitors that are known to inhibit the cognate cell bound protease activities, including several known inhibitors of metalloproteases (14) . Compound 3, a hydroxamic acid based metalloprotease inhibitor, was the only compound that inhibited the constitutive cleavagesecretion of gACE (14, 17) . The last 2 lanes of Figs 1B and 1D , show that Compound 3 added simultaneously with pervanadate, inhibited completely the stimulatory effect of pervanadate or PAO on gACE cleavage-secretion. These results indicate that similar metalloprotease(s) with an unique inhibitor profile is involved in the constitutive as well as pervanadate stimulated cleavage-secretion of ACE.
ACE present at the cell surface is cleaved by pervanadate
Using immunocytochemistry, we have shown previously that ACE is expressed at the cell surface, which can be easily visualized by indirect immunofluoresence using anti-ACE antibody and fluorescein conjugated anti-IgG (22, 18) . In the experiment shown in Fig 2, similarly stained ACE89 cells, were analyzed by FACS, and revealed abundant ACE expression at the cell surface (Fig 2A, To determine if such a mechanism is involved in pervanadate induced shedding of ACE, we used two different strategies. Cell surface ACE was labeled with biotin at 4ºC, a temperature at which endocytosis is blocked, and its cleavage-secretion was monitored, at 16ºC, a temperature that blocks internalization of not all but many cell surface proteins (24, 25) . In addition, recycling of proteins was inhibited by monensin in another experiment, also performed at 16ºC. Biotin labeled cell surface ACE, after pervanadate treatment, was quantitated by immunoprecipitation either with ACE antibody or with streptavidin-agarose, followed by Western analysis with streptavidin-horseradish peroxidase or ACE antibody respectively. Table 1 shows that using either assay, pervanadate treatment increased cleavage-secretion of biotinylated cell surface ACE. A similar increase in cleavage-secretion was also observed when monensin treated, cellsurface biotinylated, ACE 89 cells were incubated with pervanadate at 16ºC; a condition where endocytosis as well as recycling is absent or reduced substantially. Thus, it appears that enhanced shedding of ACE by pervanadate treatment, occurs primarily by its cleavage at the cell surface.
Pervanadate enhances tyrosine phosphorylation of ACE and cellular proteins that co-purify with ACE
As pervanadate is known to stabilize tyrosine phosphorylation of cellular proteins, its effect on the tyrosine phosphorylation state of ACE and ACE-associated proteins were determined. For this purpose ACE89 cells were metabolically labeled, and ACE, with the cellular proteins bound to it, were isolated from detergent extracts of ACE89 cells. This was accomplished either by binding to an affinity resin consisting of lisinopril, a competitive inhibitor of ACE or by immunoprecipitation with ACE antibody. After extensive washing, the proteins bound to the affinity column or present in the immunoprecipitate were eluted, and separated by SDS-PAGE (18). The separated proteins were then Western blotted using antiphosphotyrosine antibody. Several distinct tyrosine phosphorylated proteins were eluted from the lisinopril column when the extract was prepared from pervanadate treated ACE89 cells ( Among the tyrosine phosphorylated ACE-related species shown in lanes 2, 6 and 7 (indicated by arrows), the top two bands corresponded with the 116 KDa and 95 KDa ACE shown in lanes 3, 4 (also see Fig 1B and D) . This raised the possibility that ACE itself might be phosphorylated on one or more of its tyrosine residue(s). To test this possibility, tyrosine phosphorylated proteins were immunoprecipitated from pervanadate treated cell extract by phosphotyrosine antibody and the immunoprecipitated phosphoproteins, after SDS-PAGE, were immunoblotted with two different ACE antibodies (Fig 3, lanes 8 and 9) . Two of the phosphoproteins were recognized by both anti-ACE antibodies, a major 116 kDa and a minor 95 kDa species. None were seen if a preimmune serum was used for Western blotting (lane 10).
These results strongly suggested that gACE, both mature and the underglycosylated, could be phosphorylated on their tyrosine residue(s). The additional ACE-related phosphoprotein(s) in lanes 2, 6 and 7 (indicated by the bottom arrows) could be the underglycosylated biosynthetic precursor of ACE in the ER. This idea is reinforced by our earlier observation that, when ACE mRNA was translated in vitro in the absence of added microsomal membrane, an ACE protein of 79 kDa was synthesized (26) . The other possibility is that these are ACE-associated proteins.
Identification of the tyrosine phosphorylated proteins by mass spectroscopy
To conclusively identify the nature of the tyrosine phosphorylated proteins that immunoprecipitate with ACE antibody, mass spectroscopic analysis was performed on the immunoprecipitated phosphoproteins separated by SDS-PAGE. For this purpose, ACE and its associated proteins were isolated from a large quantity of ACE89 cell extract by immunoprecipitation and a better resolution of the phosphoproteins was achieved by altering the conditions of SDS-PAGE. Several clearly distinguishable tyrosine phosphorylated proteins were visible after immunoblotting with the phosphotyrosine antibody (Fig 4A) . A duplicate lane was stained with coomassie blue and the protein bands corresponding to the tyrosine-phosphorylated proteins were cut out from the gel, digested with trypsin, and the peptides extracted from the digest were analyzed by capillary column LC-tandem mass spectrometry. The protein in each band was identified using a combination of manual sequencing and database searching using the program Turbo-Sequest. Protein 1, 2 and 3 ( Fig 4A) was clearly identified as ACE. In all three digests, all of the peptides identified (28, 25 and 30 respectively) mapped to gACE, covering 47% to 43% and 52% of gACE sequence respectively. These results confirmed that mature ACE and its underglycosylated precursors, at various stages of synthesis, were phosphorylated on their tyrosine residues.
In the digest of protein 4, two proteins were identified. BiP, also known as the glucose regulatory protein 78, was clearly the most abundant. The mass spectroscopic analysis detected 13 peptides that covered 21% of the sequence of BiP. The second protein, although much less abundant than BiP was clearly identified as ACE, based on a number of peptides. The identity of 
Phosphorylated tyrosine is in the distal ectodomain of ACE
Full length ACE has 737 residues, among which the N-terminal 658 residues constitute the extracellular domain. The proteolytic cleavage at the major cleavage site liberates a 631 residue (108 kDa) soluble ACE into the culture media, leaving a 75 residue (8 kDa) C-terminal fragment in the cell. After pervanadate treatment, unlike the cell-associated full length ACE, the C-tail fragment was not recognized by the tyrosine phosphate antibody (data not shown). This suggested that the phosphotyrosine residue was not present in the intracellular -, transmembrane -, or the juxtamembrane domain. Thus, the distal ectodomain of ACE, which is secreted out, must contain the phosphotyrosine residue. Indeed, the culture media, from pervanadate treated or untreated cells, when immunoprecipitated with either ACE antibody or tyrosine phosphate antibody and Western blotted with ACE antibody, showed the presence of tyrosine phosphorylated secreted ACE (Fig 4C) . The culture media of pervanadate treated cells had a higher concentration of ACE. Thus, ACE secreted from unstimulated cells was phosphorylated on tyrosine residue(s) which was enhanced significantly upon pervanadate treatment. The reason why tyrosine phosphorylated ACE was not detected in Fig 3, lanes 1 and 5 is not yet clear. Its low abundance could be a possible reason.
Intracellular domain of ACE is not required for pervanadate mediated increase in cleavagesecretion
Although pervanadate treatment does not alter the phosphorylation state of the intracellular C-tail of gACE, which has one tyrosine residue, we wondered if the C-domain is needed for pervanadate-induced increase in cleavage-secretion. As reported earlier (19) , the absence of the entire intracellular domain of gACE results in an increase in the rate of cleavagesecretion of gACE from 16% to 41% (Fig 5, gACE 709-737) . Partial deletions did not affect the cleavage-secretion process significantly (gACE ∆730-737 and gACE ∆719-737). Presence of pervanadate in the culture media, however, increased the cleavage-secretion of all three tail deleted mutants to the same extent as that of the wild type gACE (Fig 5, right panels) . These results indicate that the intracellular C-tail of ACE is not involved in mediating the effect of pervanadate on cleavage secretion.
Pervanadate does not alter the rate of synthesis or processing of ACE
We have shown previously (26) that ACE protein undergoes sequential cotranslational and post-translational modifications as it transits through the ER and the Golgi compartment.
Such modifications include signal peptide cleavage, N-glycosylation, O-glycosylation and as we know now, phosphorylation. At or near the plasma membrane, the mature ACE molecule is cleaved by a membrane associated protease, the ACE-secretase before its ectodomain is secreted out. ACE-secretase cleaves only the mature fully glycosylated ACE, and does not have access to the ACE present in the ER or Golgi compartments (26, 17) . Hence, it is conceivable that if ACE reaches the cell surface faster, it could also be cleaved and secreted at a faster rate. To test this hypothesis, ACE89 cells were labeled for increasing lengths of time in the presence and absence of pervanadate. The newly synthesized ACE was immunoprecipitated and analyzed. Fig 6 shows that significant amount of mature ACE appears within 30 to 45 min, irrespective of the presence or absence of pervanadate. Thus, increased cleavage-secretion of ACE in response to pervanadate treatment is not due to faster posttranslational processing of ACE.
Pervanadate and PMA use different pathways to enhance the cleavage -secretion of ACE
We have shown previously that the cleavage-secretion of both isozymes of ACE is enhanced by treatment of cells with PMA (17) . To determine if pervanadate and PMA utilized similar mechanism to enhance secretion, cells were treated with different concentrations of pervanadate alone or in combination with 0.5 µM PMA. Figure 7A shows that PMA alone increased gACE secretion from 16% to 58%. Pervanadate, up to a concentration of 200 µM, added to the cells along with PMA, did not significantly enhance secretion further. These results suggest that either the two agents act through a similar mechanism or that the secretory machinery, beyond a certain limit, cannot increase ACE release further. To distinguish between the two possibilities we employed a potent and specific inhibitor of PKC, bisindolylmaleimide GF109203X (27) to determine its effect on both pervanadate and PMA induced secretion. As shown in Fig. 7B , GF109203X completely inhibited the PMA-induced increase in cleavagesecretion (lanes 5-8) without affecting the pervanadate-induced cleavage to any significant degree (lanes 9-12). GF109203X alone did not alter cleavage-secretion (lanes 1-4) . Moreover, pervanadate treatment, as expected, showed increased tyrosine phosphorylation of anti-ACE immunoprecipitated proteins, which was unaffected by GF109203X treatment (Fig. 7C, lanes 5 and 6). PMA treatment, in contrast, was not accompanied by any change in the tyrosine phosphorylation state of anti-ACE immunoprecipitated cellular proteins (lanes 1-4) . Thus, PMA-induced cleavage and secretion involve activation of PKC, but do not involve tyrosine phosphorylation, whereas pervanadate's effect on ACE release is independent of PKC. 
Pervanadate mediated enhancement of cleavage-secretion is blocked by inhibitor of stressactivated protein kinase p38
The possible involvement of a protein kinase in pervanadate-mediated enhancement of cleavage-secretion was explored in the next series of experiments. In separate experiments, ACE89 cells were pre-treated with inhibitors of several known protein kinases. Cells were then pulse labeled with 35 S-methionine for 30 min, and chased for 2h in the presence of pervanadate,
with the inhibitors present throughout the experiment. ACE was immunoprecipitated from the cell extract and media, and the rate of cleavage-secretion was determined as described in Fig 1B. As shown in Fig 8A, presence in culture media of potent inhibitors of many protein kinases known to be involved in different cellular signaling pathways, did not have any significant effect on pervanadate-mediated enhancement of cleavage-secretion. This indicated that mitogenactivated protein kinase/extracellular signal-regulated kinase, phosphoinositide 3-kinase, Src kinase, Janus kinase 2, p70 S6 kinase, phospholipase Cγ or PKC, are not involved in this process.
Only SB203580, an inhibitor of protein kinase p38, significantly blocked the pervanadateinduced cleavage-secretion (Fig 8A, first three bars) . Indeed, SB202474, an inactive isomer of SB203580, failed to inhibit cleavage-secretion of ACE in response to added pervanadate, confirming its specificity (Fig 8B, lanes 1,2,7-12 ). The pervanadate induced cleavage-secretion was reduced from 62 ± 9% to 25 ± 5% in the presence of SB203580.
Pervanadate increases cleavage-secretion of sACE by primary kidney cell
Data presented thus far show that in a transfected system, pervanadate treatment enhanced tyrosine phosphorylation of cellular proteins and increased the cleavage-secretion of gACE. Somatic ACE, the other isozyme of ACE which is present in serum and various other body fluids, is derived in vivo from vascular endothelial and kidney epithelial cell-associated sACE. To determine if pervanadate would evoke a similar response on cleavage-secretion of endogenous sACE in a physiologically relevant cell system, primary cultures of rabbit RTE cells were utilized. The endogenous enzymatically active sACE present in these cells is cleaved and secreted out into the culture media for several hours (15) . When pervanadate was added to the culture media, the secretion of sACE was enhanced significantly, as determined by the increase in sACE activity in the culture media (Fig 9A) . Consequently, the cell-associated sACE activity was reduced much more rapidly in pervanadate-treated cells than in untreated cells (Fig. 9B ). But, whether the angiotensin II generated in the serum (by soluble sACE) and that generated in the endothelial tissue (by endothelial cell-associated sACE) is equally efficient in maintaining blood pressure is still controversial. Utilizing the transgenic technology, the role of ACE, either as cell-associated or as a soluble molecule is now being determined (29, 30) . This is pressure. These results demonstrate that secreted ACE alone is insufficient for maintaining blood pressure, expression of endothelial cell-associated ACE was critical (29) . In direct contrast, another study also using genetically altered mice, showed that serum sACE levels alone, in the absence of endothelial cell-associated sACE, maintained normal blood pressure (30) . Although further experimental approaches are required to clarify these apparently contradictory reports, it is evident that the natural cleavage-secretion process that determines the balance between soluble and cell-associated sACE, is an important biological regulatory process for maintenance of blood pressure.
DISCUSSION
We and others have shown that soluble ACE is generated from the cell associated ACE by a regulated proteolytic cleavage by a metalloprotease, ACE-secretase. The first and the only secretase/sheddase which has been purified, cloned and studied in great detail, is tumor necrosis factor α (TNF-α) converting enzyme (TACE) (31, 32) . TACE-deficient cell populations derived from mice lacking this protease, were found to be grossly deficient in activated shedding of a wide variety of structurally and functionally diverse ectoproteins in addition to TNF-α, including tumor growth factor-α, L-selectin, p75 TNF receptor and β-amyloid precursor protein (28, (33) (34) (35) . TACE is thus regarded as a common protease needed for shedding in general. Unlike these ectoproteins, ACE was cleaved and secreted normally when transfected in the TACE deficient cells, demonstrating that TACE is not the secretase responsible for the generation of soluble ACE under physiological conditions (16) . This conclusion is reinforced by the observation that C-terminally truncated soluble sACE is present in TACE-deficient mice as it is in its wild type counterpart. In addition, sACE was present in the serum of MDC9 and MDC15 knockout mouse, the two other metalloprotease-disintegrins implicated in cleavage-secretion (Sen, I., and Blobel, C.P., unpublished observation). To our knowledge, in addition to ACE, only one other ectoprotein, the cytokine TRANCE, has been shown to be shed normally by the TACE deficient cells. These observations, taken together, indicate that ACE is cleaved and secreted by a novel secretase. In this communication we report the identification of signaling cascades that is involved in regulating ACE shedding.
Gutwein, et. al. while studying the cleavage-secretion of adhesion molecule L1, observed that in addition to direct cell surface proteolysis and shedding, L1 was also cleaved by a different pathway. Based on ADAM10 localization, these authors provide evidence that, upon pervanadate treatment, microvesicles containing full-length L1 and the active form of ADAM10
were released into the culture media, and L1 cleavage occurred in these vesicles. Only neural L1
form carrying the RSLE signal for clathrin-dependent endocytosis was recruited and cleaved in vesicles. Our results (Table 1) show that pervanadate induced cleavage of ACE in ACE 89 cells does not follow this alternative cleavage pathway. Similar to pervanadate induced increased shedding of ACE at 37ºC, shedding was also increased in the presence of pervanadate, at reduced temperature and in the presence of monensin, a condition at which endocytosis and recycling are absent or significantly decreased. Following the procedure of Gutwein, et. al., we isolated the vesicle fraction from the culture media of ACE 89 cells in the presence and the absence of pervanadate. Under both conditions, negligible amount of ACE (2% to 3% of total ACE present in the culture media, all of which was of the cleaved variety) was found in the vesicular fraction (data not shown). Thus, unlike L1, ACE does not appear to be included in the vesicle fraction.
This difference could be attributed to the fact that cytoplasmic tail of ACE does not contain the signal for clathrin-dependent endocytosis.
Tyrosine phosphorylated proteins that co-immunoprecipitate with ACE after pervanadate treatment of ACE89 cells, were identified using two different strategies, immunoreactivity with tyrosine phosphate antibody and direct sequencing of the phosphoproteins by mass-spectroscopy.
Among the immunoprecipitated phosphoproteins, one was identified as mature ACE and two others as underglycosylated precursors of ACE (Fig 4, bands 1-3) . The fourth phosphorylated protein (band 4) was BiP, an ER-resident chaperone protein. Phosphorylation of BiP or ACE on tyrosine residue in vivo, has not been reported before, although, in vitro BiP has been shown to act as a substrate for Src kinase (36) . We believe that ACE tyr-phosphorylation takes place in the ER, because the endoglycosidase-H sensitive underglycosylated ACE, which is present in the ER (26) was found to be extensively phosphorylated (Fig 4, band 2) . Optimal intracellular transport of ACE during its synthesis and processing requires a transient interaction of BiP with ACE, but their continued association impairs the proper transit of ACE to the next stage of processing (18) .
It is possible that, if ACE appeared at the cell surface faster, it could also be cleaved at a faster rate. As illustrated in Fig 6, pervanadate treatment did not influence the transit time of ACE between ER and plasma membrane. In other words, enhancement of cleavage-secretion by pervanadate is not due to faster processing of ACE.
How pervanadate influences cleavage-secretion of ACE is not clear yet, but, as this process does not require protein synthesis, it is likely that phosphorylation and dephosphorylation plays an important role. As ACE does not have tyrosine kinase activity, pervanadate could mediate its action by modifying the phosphorylation state of ACE-secretase, or other as yet unidentified cellular proteins, in addition to ACE and BiP. These modifications then directly or indirectly could influence cleavage-secretion. Modification of the cytoplasmic domain of many proteins is often considered key to interaction with other cellular proteins, leading to a particular cellular event. Although the 30 residue ACE-cytoplasmic tail has one tyrosine residue, that residue is not phosphorylated upon pervanadate treatment. The 8kDa C-tail fragment which was left in the cell after the ectodomain of ACE was cleaved off was not tyrosine phosphorylated and the cleavage-secretion of a cytoplasmic tail deleted mutant ACE was also enhanced by pervanadate, indicating that the presence of the cytoplasmic tail is not essential for this response (Fig 5) . Similar to ACE shedding, TGFα, β-amyloid precursor protein, syndecan (37, 38) or L1 adhesion molecule shedding does not appear to depend on the cytoplasmic tail sequences (39) . The cytoplasmic domain of L-selectin, on the contrary, seems to play a role in regulating its susceptibility to ectodomain shedding (40) . Also, PMA-induced increase in the cleavage-secretion of ACE was not accompanied by any increase in tyrosine phosphorylation.
Most of the secretases reported thus far are stimulated by PMA and inhibited by hydroxamic acid-based inhibitors. In ACE89 cells, the basal cleavage-secretion processes occur slowly and can be enhanced by treatment of cells with PMA, an activator of PKC. Staurosporin, an inhibitor of protein kinase C, has been shown to inhibit PMA induced secretion of sACE in
Chinese hamster ovary cells, indicating involvement of PKC. As staurosporin inhibits both PKC (41) and tyrosine kinases (42) , it is difficult to interpret its effects. The bisindolylmaleimide GF109203X, however, is a specific inhibitor of PKC and does not affect tyrosine kinases (27) .
This compound completely blocked the effect of PMA on the cleavage-secretion of gACE in ACE89 cells, but did not have any effect on the pervanadate-induced secretion (Fig 7B) . These results and the observation that PMA treatment did not show any increase in the tyrosine phosphorylation of intracellular proteins, suggested that PKC-dependent pathways do not contribute to increased tyrosine phosphorylation evoked by pervanadate. On the contrary, both pervanadate- (Fig 1B) and PMA-induced cleavage secretion (17) were abolished by the metalloprotease inhibitor Compound 3. Thus, ACE release is regulated by PKC-dependent as well as tyrosine phosphorylation-dependent pathways, both of which finally converge to a metalloprotease/ACE secretase-dependent step.
To explore further the mechanism by which pervanadate increases the shedding of ACE, the role played by different protein kinases involved in signaling was identified through the use of highly specific inhibitors of these kinases. SB203580, an inhibitor of p38 MAP kinase, was the only compound among a large number of kinase inhibitors tested, which was effective in reversing the pervanadate induced increase in ACE secretion. These results indicated that the enhancement of ACE secretion by pervanadate involves the p38 MAP kinase pathway. For a different transmembrane protein, L1, the pervanadate induced secretion is reported to be inhibited by PP2, indicating the involvement of Src-kinase (43) . This information is not available for amyloid precursor protein (44), syndecan 1 (37), ErbB-4 and amphiregulin (45), all of which exhibits increased shedding by pervanadate.
Our current and previous findings can be summarized as follows: ACE and BiP associate in the ER and a p38 dependent tyr-kinase phosphorylates both proteins. In the next step, newly synthesized tyr-phosphorylated ACE associates with specific PKC isozymes (18) . The phorbol ester PMA, added to the cells, enhances dissociation of some, but not all of the bound PKC isozymes. Both dissociation of PKC-, and by PMA and tyr-phosphorylation of ACE enhance cleavage-secretion of ACE. Many aspects of this working model are speculative at this time and further experiments will be needed to test them critically. For example, how the p38 MAPK pathway affects the tyr-phosphorylation status of ACE is unclear. Similarly, why phosphorylated ACE is cleaved better is unclear. However, the current investigation has revealed new features of ACE secretion; it is enhanced by tyr-phosphorylation, a process that presumably takes place in the ER and is promoted by the action of the p38 MAPK pathway. The protein bands in the gel corresponding to the bands in the blot (marked by arrows 1 to 4, on the right), were cut out and the gel slices were used for in-gel digestion by trypsin and analyzed by mass spectrometry for identification of the protein as described in "Experimental Procedures". B) ACE89 cell extracts were used for immunoprecipitation (IP) with anti-ACE antibody (anti-ACE) or tyrosine phosphate antibody (anti-P-tyr). The immunoprecipitates were analyzed by SDS-PAGE followed by Western blotting (WB) using anti BiP antibody (anti-BiP).
C) ACE89 cells (two 150 mm plates, 90% confluent) were incubated with (+) or without (-) pervanadate (100 µM) for 3 h. Entire media from both plates treated similarly were combined, and then divided into two equal parts and immunoprecipitated with tyrosine phosphate antibody (IP:Anti-P-tyr) or anti ACE antibody (IP: Anti-ACE). After SDS-PAGE and transfer to nitrocellulose, the membranes were Western blotted with Anti-ACE antibody. The result shown is representative of three different experiments. 
